Ocular Therapeutix (OCUL) Tops Q2 EPS by 16c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($2.10), $0.16 better than the analyst estimate of ($2.26). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Pfizer lung cancer drug misses survival goal in Phase 3 trial